10 Heart Attack Clinical Trials in Hackensack, NJ (2026)

Q: How do I join a clinical trial in Hackensack?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Hackensack research site will contact you.

Recruiting Heart Attack Studies in Hackensack

NCT07140939Recruiting

A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat

A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat....

Hackensack, NJPHASE3320 participantsCaliway Biopharmaceuticals Co., Ltd.

View Study Details

NCT04256317Recruiting

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms and a Phase 1 Combination Therapy arm Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) us...

Hackensack, NJPHASE2316 participantsTaiho Oncology, Inc.

View Study Details

NCT03802695Recruiting

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transpla...

Hackensack, NJPHASE1300 participantsOrca Biosystems, Inc.

View Study Details

NCT06733935Recruiting

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells ...

Hackensack, NJPHASE1240 participantsNkarta, Inc.

View Study Details

NCT03813407Recruiting

An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia

Sodium zirconium cyclosilicate has been shown to be effective and safe in adults for the treatment of hyperkalaemia, and therefore it is expected to be beneficial in children. This study will evaluate...

Hackensack, NJPHASE3140 participantsAstraZeneca

View Study Details

NCT06824168Recruiting

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

This clinical two-arm trial is designed to evaluate two doses of quizartinib as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem...

Hackensack, NJPHASE2130 participantsDaiichi Sankyo

View Study Details

NCT06098430Recruiting

Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

There is a pressing need to measure patient-reported symptoms in patients of all ages diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). This study aims to measure longitudinal sy...

Hackensack, NJ100 participantsSt. Jude Children's Research Hospital

View Study Details

NCT04895436Recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previousl...

Hackensack, NJPHASE275 participantsAbbVie

View Study Details

NCT04990102Recruiting

Phase IB/II of CPX-351 for Relapse Prevention in AML

This is a phase IB/II study with a 3+3 dose de-escalation study design. Patients will continue maintenance treatment with CPX-351 for 6 cycles on D1 and D3, as long as patient remains in CR. The dose ...

Hackensack, NJPHASE124 participantsGeorgetown University

View Study Details

NCT06248515Recruiting

A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors

The goal of this clinical trial is to study the effect of sacituzumab govitecan-hziy in adult patients with advanced thymoma and thymic carcinoma after progressing on at least one prior line of therap...

Hackensack, NJPHASE218 participantsGeorgetown University

View Study Details

About Heart Attack Clinical Trials in Hackensack

A heart attack (myocardial infarction) occurs when blood flow to part of the heart muscle is blocked, usually by a blood clot. It is a medical emergency requiring immediate treatment. Long-term management includes medications, lifestyle changes, and cardiac rehabilitation.

There are currently 10 heart attack clinical trials recruiting participants in Hackensack, NJ. These studies are seeking a combined 1,663 participants. Research is being sponsored by Caliway Biopharmaceuticals Co., Ltd., Taiho Oncology, Inc., Orca Biosystems, Inc. and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Heart Attack Clinical Trials in Hackensack — FAQ

Are there heart attack clinical trials in Hackensack?

Yes, there are 10 heart attack clinical trials currently recruiting in Hackensack, NJ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Hackensack?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Hackensack research site will contact you about next steps.

Are clinical trials in Hackensack free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Hackensack studies also compensate for your time and travel.

What heart attack treatments are being tested?

The 10 active trials in Hackensack are testing new therapies including novel drugs, biologics, and treatment approaches for heart attack.

Data updated October 12, 2026 from ClinicalTrials.gov